| Literature DB >> 35372322 |
Jonathan Picker1, Ziyang Lan2, Srishtee Arora1, Mykel Green2, Mariah Hahn3, Elizabeth Cosgriff-Hernandez2, Magnus Hook1.
Abstract
Collagens are the major structural component in animal extracellular matrices and are critical signaling molecules in various cell-matrix interactions. Its unique triple helical structure is enabled by tripeptide Gly-X-Y repeats. Understanding of sequence requirements for animal-derived collagen led to the discovery of prokaryotic collagen-like protein in the early 2000s. These prokaryotic collagen-like proteins are structurally similar to mammalian collagens in many ways. However, unlike the challenges associated with recombinant expression of mammalian collagens, these prokaryotic collagen-like proteins can be readily expressed in E. coli and are amenable to genetic modification. In this review article, we will first discuss the properties of mammalian collagen and provide a comparative analysis of mammalian collagen and prokaryotic collagen-like proteins. We will then review the use of prokaryotic collagen-like proteins to both study the biology of conventional collagen and develop a new biomaterial platform. Finally, we will describe the application of Scl2 protein, a streptococcal collagen-like protein, in thromboresistant coating for cardiovascular devices, scaffolds for bone regeneration, chronic wound dressing and matrices for cartilage regeneration.Entities:
Keywords: biomaterials; collagen; hydrogel; integrin; integrin-targeting biomaterials; prokaryotic collagen-like protein; streptococcal collagen-like protein
Year: 2022 PMID: 35372322 PMCID: PMC8968730 DOI: 10.3389/fbioe.2022.840939
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1Crystal structure of a collagen peptide with the sequence (PPG)10, accessed from PDB ID: 1K6F. The crystal structure shows the structure of the triple helical collagen. Three individual peptides are shown with green representing the leading strand of collagen, pink representing the middle strand, and blue representing the lagging strand.
FIGURE 2Domain organization of various eukaryotic and prokaryotic collagens. All numbers in parenthesis below species name and protein name is the accession number for the protein as found in the NCBI Protein database. Numbers below the domains indicate the last residue of that domain. Abbreviations are as follows: NTD = N-terminal Domain, CTD = C-terminal Domain, V = Trimerization Domain, C = C-terminal domain and anchor to cell membrane, N = N-terminal Domain and anchor to cell membrane, CLR = Collagen-like Region.
Characteristics of eukaryotic collagens and prokaryotic collagen-like proteins.
| Eukaryotic collagen | Prokaryotic collagen-like protein | References | |
|---|---|---|---|
| Domain Organization | Has a N-terminal domain, a collagen region, and a C-terminal domain | Has a N-terminal domain, a collagen region, and a C-terminal domain |
|
| Might have some interruptions within the collagen region | Might have some interruptions within the collagen region |
| |
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
| Residue Composition of collagen region (X/Y) | Gly-X-Y (Percentages based on human collagen) | Gly-X-Y |
|
| X: 31.1% Proline (fibrillar), 24.6% Proline (non-fibrillar) | X: 31.0% Proline (Gram-positive), 19% Proline (all bacteria) |
| |
| Y: 33.5% Proline/hydroxyproline (fibrillar), 42.2% Proline/hydroxyproline (non-fibrillar) | Y: 48.3% Threonine (Gram-positive), 31.6% Threonine (all bacteria) | ||
| Post-translational modification | Hydroxylation of proline to hydroxyproline and lysine to hydroxylysine, glycosylation of hydroxylysine residues, removal of N-terminal and C-terminal pro-peptides, and cross-linking of lysine and hydroxylysine residues | In most cases, there is no hydroxylation of proline to hydroxyproline, no glycosylation of the collagen structure, and no cleavage of the protein |
|
| A limited number of bacteria have their own post-translational modifications, allowing for hydroxylation, glycosylation, or cleavage of proteins |
| ||
|
| |||
|
| |||
| Function | Provides mechanical properties (load bearing, tensile strength, and torsional stiffness), cell signaling either directly or through other ECM components, filtration, adhering materials together | Adhesion to specific environments, formation of biofilm, internalization into host, evasion of immune system, use for motility, and spore formation |
|
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
| Location | Present within the matrix, with some cellular receptor binding (such as integrin) | N-terminal or C-terminally bound to bacteria cell wall, Bucl8 has two outer transmembrane domains |
|
| A few collagens can be found integrated within cell membranes |
| ||
|
| |||
|
| |||
| Ability to form superstructures | Fibrillar collagen can come together to form larger fibrils, fascicles, and tendons | Unable to form larger superstructures, none are currently known |
|
|
| |||
|
| |||
|
|
Binding sites on human collagen to various ECM proteins and cellular receptors. Symbol Definition: * - computational modeling used to define residues, ∼ denotes protease cut site in the protein sequence, † protease cut site was determined using Mass Spectroscopy, “O/P” means that both hydroxyproline and proline have been used and were shown to interact, “x” represents any amino acid unless otherwise stated.
| Target protein | Collagen binding site | Investigated using | References |
|---|---|---|---|
| Decorin | “Gx1x2GDR GEx3GP site, where x1 = K or A, x2 = N, K, S, or P, x3 = P or T” * | Full-length Type I Collagen Fibril |
|
| Biglycan | Known to share a binding domain with decorin, though exact residues are unknown | Full-length Type I Collagen |
|
| Discoidin Domain Receptor 1 | GVMGFO | Synthetic collagen peptide |
|
| Discoidin Domain Receptor 2 | GVMGFO +2 other sites | Synthetic collagen peptide |
|
|
| |||
| Integrin α1β1 | GF″O/P″GEN, GF″O/P″GER, GLOGER, GASGER, GVOGEA, and GLOGEN | Synthetic collagen peptide & Prokaryotic collagen-like protein |
|
|
| |||
|
| |||
|
| |||
| Integrin α2β1 | GF″O/P″GER | Synthetic collagen peptide & Prokaryotic collagen-like protein |
|
|
| |||
|
| |||
|
| |||
|
| |||
| Integrin α10β1 | GFOGER | Synthetic collagen peptide |
|
| Integrin α11β1 | GFOGER | Synthetic collagen peptide |
|
|
| |||
| Fibronectin | GLAGQR GIVGLP GQRGER | Prokaryotic collagen-like protein & Synthetic collagen peptide |
|
|
| |||
| Secreted protein, acidic and rich in cysteine known as “SPARC” | GPOGPS GPRGQO GVMGFO GPKGND GAO | Cyanogen bromide peptides & Synthetic collagen peptide |
|
| Osteopontin | Binds Type I Collagen at an unknown binding site | Full-length Type I Collagen |
|
| GpVI | GAOGLR GGAGPO GPEGGK GAAGPO GPO, (POG)10 | Synthetic collagen peptide |
|
|
| |||
| Collagen V | Cross-linked in LPQPPQ EKAHDG GRY region | Full-Length Type I Collagen |
|
| Platelet derived growth factor-BB | Binds Type 1 Collagen at an unknown binding site | Full-length Type I Collagen |
|
| Endo180/uPARAP | GPPGPP GPPGPP GPPSAG FDFSFL PQPPQE KAHDGG RYYRA | Full-length Collagen |
|
|
| |||
|
| |||
| Thrombospondin1 | Known to bind to Type I, VI, XI Collagen, and to Endostatin | Full-length Collagen |
|
| THBS1 | |||
| Procollagen C-proteinase enhancer-1 (PCPE-1) | Binds to the C-terminal propeptide region, the lysine residues C-terminal of the BMP-1 cut site on α1 Type III Collagen | Type I Procollagen, & recombinant Type III Collagen C-propeptide |
|
|
| |||
| Bone morphogenetic protein-1 (BMP-1) | YRA ∼ DDA NVVRDR D α1 (I) | Type I and III Procollagen |
|
| YRA ∼ DQP RSAPSL R α2 (I) |
| ||
| YYG ∼ DEP MDFKIN T α1 (III) | |||
| SMADs | C-terminal propeptide of Type I, III, and V Collagen | Recombinant Type I, III, and V Collagen C-propeptide |
|
| Osteoclast-associated receptor (OSCAR) | GxOGPx GFx, GPOGPA GFO, GAOGAS GDR | Synthetic collagen peptide |
|
|
| |||
|
| |||
| Bone SialoProtein-2 | In the triple-helical region of Type I Collagen, and a binding site within Type XI Collagen KKKSNY TKKKRT LATNSK KKSKM, KKKSNY TKKKRT LATNSK KK | Type I Collagen (treated with pepsin), & peptides of non-collagen regions of Type XI Collagen |
|
|
| |||
| Periostin | Binds Type I and V Collagen with an unknown binding site | Full-length Type I and V Collagen |
|
|
| |||
|
| |||
|
| |||
| Pigment epithelium-derived factor (PEDF) | KGHRGF SGL, KGHRGY SGL | Synthetic collagen peptide |
|
|
| |||
| Heparin | GBBGB, where “B” is a base residue | Type I Collagen, Prokaryotic collagen-like protein, & Synthetic collagen peptide |
|
| GRPGKR GKQGQK, RGTPGK PGPRGQ RGPTGP RGERGPR, GRKGR, GKRGK |
| ||
|
| |||
|
| |||
|
| |||
| Heparan-Sulfate | KGHRGF, RGTPGK PGPRGQ RGPTGP RGERGPR | Type I Collagen & Synthetic collagen peptide |
|
|
| |||
|
| |||
|
| |||
| Leukocyte associated Ig-like receptor-1 (LAIR-1) | GAOGLR GGAGPO GPEGGK GAAGPO GPO | Synthetic collagen peptide |
|
| Heat Shock Protein-47 (HSP47) | xGxRG | Synthetic collagen peptide |
|
| Fibromodulin | KGHR | Synthetic collagen peptide |
|
|
| |||
| Trypsin-1 | Cleaves after lysine or arginine, except when followed by proline | Human collagen, 90% Type I and 10% Type III |
|
| Only works on non-triple helical collagen |
| ||
| Elastase 2 | KLK ∼ AR, FVR ∼ NK, And GDR ∼ GL as found in Type XVII Collagen, GPLGIA GITGAR GLA in Type III Collagen | Full-length Type XVII Collagen† & recombinant Type III Collagen |
|
| Matrix Metalloproteinase-1 (MMP-1) | GPQG ∼ LA GQRGIV GLP | Prokaryotic collagen-like protein, Full-length Type I Collagen | ( |
| MMP-2 | GPQG ∼ LA GQRGVV GLP | Full-length Type I Collagen |
|
|
| |||
| MMP-8 | GPQG ∼ LA GQRGVV GLP | Full-length Type I Collagen |
|
|
| |||
| MMP-13 | G ∼ LAGQR GIVGLO GQRGER, GLOGER GRTGPA GAAGAR | Synthetic collagen peptide |
|
| Prolyl-4-hydroxylase (P4H) | “X”PG, with “X” being preferred to be Proline | Synthetic collagen peptide |
|
|
| |||
|
| |||
| von Willebrand Factor (VWF) | RGQOGV MGF | Synthetic collagen peptide |
|
| Nidogen | Can bind 80 nm away from the C-terminus of Type IV Collagen, and with the ectodomain of Type XIII Collagen | Full-length Type IV Collagen and recombinant Type XIII Collagen ectodomain |
|
|
|
FIGURE 3Incorporation of Scl2 proteins into hydrogels as alternative materials to animal-derived collagen matrices. (A) Scl2 protein hydrogel network with varied crosslinking modalities for enhanced gel stability. (B) Hybrid Scl2 hydrogels with the Scl2 protein anchored into a synthetic hydrogel network via a functionalization linker and the different parameters used to modulate hydrogel properties. (C) Different physcial forms of hybrid Scl2 hydrogels used in biomedical applications.
FIGURE 4Biomedical applications of Scl2-containing biomaterials with targeted integrin interactions. (A) PEG-Scl2 hydrogel coatings of cardiovascular devices to enhance thromboresistance; (B) PEG-Scl2 hydrogel that revealed integrin-mediated hMSC osteogenic differentiation via the MAPK signal pathway (C) Different types of dressings containing Scl2 proteins to enhance chronic wound healing; (D) PEG-Scl2 protein hydrogel with binding sites for chondroitin sulfate and hyaluronic acid to improve cartilage repair.